Cis-platinum associated hearing loss

Publisher Website
Google Scholar
Abstract
Cis-dichlorodiammine Pt II (cis-Pt, NSC-119875) is a metal co-ordination complex whose chemical structure is unique among chemotherapeutic agents in current clinical use. Its efficacy in the treatment of patients with testicular, bladder, ovarian and head and neck malignancy were demonstrated. Early clinical experience showed that nephrotoxicity was dose-limiting, but recently the use of prehydration and mannitol or furosemide (frusemide) infusion was recommended to protect the kidneys of patients treated with cis-Pt. Although ototoxicity was originally thought to occur only occasionally, recent studies of auditory function in patients treated with cis-Pt frequently show ototoxicity. The case report presented may indicate hearing loss associated with cis-Pt therapy.